Harnessing immune cells to leverage PARP inhibitors

Tian Li Wang; Ie Ming Shih

doi:10.1016/j.cell.2024.07.058

Harnessing immune cells to leverage PARP inhibitors

Tian Li Wang^*
, Ie Ming Shih

^*Corresponding author for this work

School of Medicine

Johns Hopkins University

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Abstract

Homologous-recombination deficiency in DNA repair characterizes a unique group of cancers that are vulnerable to PARP inhibitors and cytotoxic chemotherapy. In this issue of Cell, Luo et al., demonstrated that this genetic attribute in cancer cells may reprogram tumor immune microenvironment and show promise of targeting effector-Treg cells.

Original language	English
Pages (from-to)	4829-4830
Number of pages	2
Journal	Cell
Volume	187
Issue number	18
DOIs	https://doi.org/10.1016/j.cell.2024.07.058
State	Published - 05 09 2024

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
Humans
Tumor Microenvironment
Neoplasms/drug therapy
T-Lymphocytes, Regulatory/immunology
Animals

Access to Document

10.1016/j.cell.2024.07.058

Cite this

@article{4ea19df256d84ffdb7a17d5f6bacddc4,

title = "Harnessing immune cells to leverage PARP inhibitors",

abstract = "Homologous-recombination deficiency in DNA repair characterizes a unique group of cancers that are vulnerable to PARP inhibitors and cytotoxic chemotherapy. In this issue of Cell, Luo et al., demonstrated that this genetic attribute in cancer cells may reprogram tumor immune microenvironment and show promise of targeting effector-Treg cells.",

keywords = "Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use, Humans, Tumor Microenvironment, Neoplasms/drug therapy, T-Lymphocytes, Regulatory/immunology, Animals",

author = "Wang, \{Tian Li\} and Shih, \{Ie Ming\}",

year = "2024",

month = sep,

day = "5",

doi = "10.1016/j.cell.2024.07.058",

language = "英语",

volume = "187",

pages = "4829--4830",

journal = "Cell",

issn = "0092-8674",

publisher = "Elsevier B.V.",

number = "18",

}

TY - JOUR

T1 - Harnessing immune cells to leverage PARP inhibitors

AU - Wang, Tian Li

AU - Shih, Ie Ming

PY - 2024/9/5

Y1 - 2024/9/5

N2 - Homologous-recombination deficiency in DNA repair characterizes a unique group of cancers that are vulnerable to PARP inhibitors and cytotoxic chemotherapy. In this issue of Cell, Luo et al., demonstrated that this genetic attribute in cancer cells may reprogram tumor immune microenvironment and show promise of targeting effector-Treg cells.

AB - Homologous-recombination deficiency in DNA repair characterizes a unique group of cancers that are vulnerable to PARP inhibitors and cytotoxic chemotherapy. In this issue of Cell, Luo et al., demonstrated that this genetic attribute in cancer cells may reprogram tumor immune microenvironment and show promise of targeting effector-Treg cells.

KW - Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use

KW - Humans

KW - Tumor Microenvironment

KW - Neoplasms/drug therapy

KW - T-Lymphocytes, Regulatory/immunology

KW - Animals

UR - https://www.scopus.com/pages/publications/85203613907

U2 - 10.1016/j.cell.2024.07.058

DO - 10.1016/j.cell.2024.07.058

M3 - 评论/辩论

C2 - 39241744

AN - SCOPUS:85203613907

SN - 0092-8674

VL - 187

SP - 4829

EP - 4830

JO - Cell

JF - Cell

IS - 18

ER -

Harnessing immune cells to leverage PARP inhibitors

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this